ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Arsenic Trioxide

Also written as “arsenic trioxide”, “IV Arsenic Trioxide” and “Treatment A: Arsenic Trioxide (ATO) Intravenous”.

Its studies are mostly in Leukemia, Promyelocytic, Acute · Multiple Myeloma · Bronchiolitis Obliterans Syndrome · Leukemia · Leukemia, Myeloid, Acute, led by 6 companies.

Drug pageArsenic Trioxide: every studyMany companies study it; this page follows only the 9 they lead. All 118 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 6, 20019 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Swedish Orphan Biovitrumits history only30 open or runningphase 2since Jun 6, 2001Jun 6, 2001none ahead
SDK Therapeuticsits history only21 open or runningphase 3since Dec 16, 2025Jan 23, 2025Jun 2027phase 3 · NCT07296445
Medsenicits history only10 open or runningphase 2since Oct 28, 2016Oct 28, 2016none ahead
Oncotherapeuticsits history only10 open or runningphase 2since Jun 10, 2004Jun 10, 2004none ahead
Syros Pharmaceuticals10 open or runningphase 1since Aug 3, 2021Aug 3, 2021none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Aug 6, 2007Aug 6, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2021First study: phase 1 study in Leukemia, Promyelocytic, AcuteFirst studyNCT04996030 · 16 enrolled · United States

TargetBeta

TXNRD1 →read by rule
“Thioredoxin reductase 1 inhibitor”ChEMBL 37, by rule

Studies

The one study Syros Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04996030Leukemia, Promyelocytic, Acute · United States1SuspendedJan 3, 202416

How it is read

Names in the registry

  • “arsenic trioxide”, 4 entries
  • “IV Arsenic Trioxide”, 1 entry
  • “Treatment A: Arsenic Trioxide (ATO) Intravenous”, 1 entry
  • “Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state”, 1 entry
  • “Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.